AR091065A1 - Una formulacion farmaceutica que comprende un quelato de oligonucleotidos antiviral para el tratamiento de una infeccion antiviral - Google Patents
Una formulacion farmaceutica que comprende un quelato de oligonucleotidos antiviral para el tratamiento de una infeccion antiviralInfo
- Publication number
- AR091065A1 AR091065A1 ARP130101695A ARP130101695A AR091065A1 AR 091065 A1 AR091065 A1 AR 091065A1 AR P130101695 A ARP130101695 A AR P130101695A AR P130101695 A ARP130101695 A AR P130101695A AR 091065 A1 AR091065 A1 AR 091065A1
- Authority
- AR
- Argentina
- Prior art keywords
- pharmaceutical formulation
- oligonucleotide
- chelate
- treatment
- oligonucleotide chelate
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7115—Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/712—Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7135—Compounds containing heavy metals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Biochemistry (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Genetics & Genomics (AREA)
- Neurosurgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Tropical Medicine & Parasitology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- AIDS & HIV (AREA)
- Pulmonology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychiatry (AREA)
- Gastroenterology & Hepatology (AREA)
- Obesity (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Diabetes (AREA)
Abstract
Se describen composiciones farmacéuticas y métodos para el tratamiento de infecciones virales, hipercolesterolemia, hipertrigliceridemia, Alzheimer, enfermedades causadas por priones y distrofia muscular de Duchenne con quelatos de oligonucleótidos. Reivindicación 6: La formulación farmacéutica de cualquiera de las reivindicaciones 1 - 5, donde dicho quelato de oligonucleótidos se prepara con un catión metálico divalente. Reivindicación 11: La formulación farmacéutica de cualquiera de las reivindicaciones 1 - 5, donde dicho quelato de oligonucleótidos comprende calcio y magnesio. Reivindicación 12: La formulación farmacéutica de cualquiera de las reivindicaciones 1 - 5, donde dicho quelato de oligonucleótidos comprende al menos un oligonucleótido de cadena doble. Reivindicación 13: La formulación farmacéutica de cualquiera de las reivindicaciones 1 - 5, donde dicho quelato de oligonucleótidos comprende al menos un oligonucleótido con al menos un enlace de fosforotioato. Reivindicación 15: La formulación farmacéutica de cualquiera de las reivindicaciones 1 - 5, donde dicho quelato de oligonucleótidos comprende al menos un oligonucleótido con una ribosa modificada en la posición 2. Reivindicación 16: La formulación farmacéutica de cualquiera de las reivindicaciones 1 - 5, donde dicho quelato de oligonucleótidos comprende al menos un oligonucleótido que tiene cada ribosa en la posición 2 O-metilada. Reivindicación 18: La formulación farmacéutica de cualquiera de las reivindicaciones 1 - 5, donde dicho quelato de oligonucleótidos comprende al menos un oligonucleótido, donde cada citosina es 5metilcitosina. Reivindicación 21: Una formulación farmacéutica que comprende un quelato que comprende SEQ ID Nº 20 para el tratamiento de la hipercolesterolemia. Reivindicación 22: Una formulación farmacéutica que comprende un quelato que comprende SEQ ID Nº 19 para el tratamiento de la distrofia muscular de Duchenne. Reivindicación 23: Una formulación farmacéutica que comprende un quelato que comprende SEQ ID Nº 7 para el tratamiento de una infección por Hepatitis C. Reivindicación 24: La formulación farmacéutica de cualquiera de las reivindicaciones 1 - 5 y 21 - 23, donde dicho quelato de oligonucleótidos se formula para una administración subcutánea. Reivindicación 25: La formulación farmacéutica de cualquiera de las reivindicaciones 1 - 5 y 21 - 23, donde dicho quelato de oligonucleótidos se formula para una inyección intravenosa.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261648694P | 2012-05-18 | 2012-05-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR091065A1 true AR091065A1 (es) | 2014-12-30 |
Family
ID=49581827
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP130101695A AR091065A1 (es) | 2012-05-18 | 2013-05-16 | Una formulacion farmaceutica que comprende un quelato de oligonucleotidos antiviral para el tratamiento de una infeccion antiviral |
Country Status (37)
| Country | Link |
|---|---|
| US (1) | US9616083B2 (es) |
| EP (1) | EP2849760B1 (es) |
| JP (2) | JP6294308B2 (es) |
| KR (1) | KR101975915B1 (es) |
| CN (1) | CN104379152B (es) |
| AR (1) | AR091065A1 (es) |
| AU (1) | AU2013262415B2 (es) |
| BR (1) | BR112014028568B1 (es) |
| CA (1) | CA2873526C (es) |
| CL (1) | CL2014003135A1 (es) |
| CO (1) | CO7131388A2 (es) |
| CR (1) | CR20140522A (es) |
| CU (1) | CU20140132A7 (es) |
| CY (1) | CY1122856T1 (es) |
| DK (1) | DK2849760T3 (es) |
| DO (1) | DOP2014000263A (es) |
| EA (1) | EA034799B1 (es) |
| EC (1) | ECSP14027542A (es) |
| ES (1) | ES2767333T3 (es) |
| HK (1) | HK1206259A1 (es) |
| HR (1) | HRP20200045T1 (es) |
| HU (1) | HUE047456T2 (es) |
| IL (1) | IL235402B (es) |
| IN (1) | IN2014DN08982A (es) |
| LT (1) | LT2849760T (es) |
| MX (1) | MX360626B (es) |
| MY (1) | MY168209A (es) |
| NZ (1) | NZ701931A (es) |
| PH (1) | PH12014502484B1 (es) |
| PL (1) | PL2849760T3 (es) |
| PT (1) | PT2849760T (es) |
| RS (1) | RS59914B1 (es) |
| SG (1) | SG11201407261XA (es) |
| SI (1) | SI2849760T1 (es) |
| TW (1) | TWI648288B (es) |
| WO (1) | WO2013170385A1 (es) |
| ZA (1) | ZA201408082B (es) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105641700B (zh) | 2007-10-26 | 2021-01-01 | 莱顿教学医院 | 对抗肌肉病症的方式和方法 |
| EP2119783A1 (en) | 2008-05-14 | 2009-11-18 | Prosensa Technologies B.V. | Method for efficient exon (44) skipping in Duchenne Muscular Dystrophy and associated means |
| CA3120918A1 (en) | 2012-01-27 | 2013-08-01 | Biomarin Technologies B.V. | Rna modulating oligonucleotides with improved characteristics for the treatment of duchenne and becker muscular dystrophy |
| AU2013308045B2 (en) | 2012-08-30 | 2018-10-04 | Replicor Inc. | Methods for the treatment of hepatitis B and hepatitis D infections |
| UA124521C2 (uk) | 2015-04-23 | 2021-10-05 | Джерон Корпорейшн | Способи отримання полінуклеотидів з використанням композицій солей полівалентних катіонів |
| CN108513546A (zh) | 2015-10-28 | 2018-09-07 | 克里斯珀医疗股份公司 | 用于治疗杜氏肌营养不良症的材料和方法 |
| CN117683769A (zh) * | 2015-12-23 | 2024-03-12 | 瑞普鲁卡私人有限公司 | 核酸寡聚体及其用途 |
| US11166976B2 (en) | 2018-11-08 | 2021-11-09 | Aligos Therapeutics, Inc. | S-antigen transport inhibiting oligonucleotide polymers and methods |
| WO2022229350A2 (en) | 2021-04-30 | 2022-11-03 | Tirmed Pharma Ab | Single-stranded oligonucleotides for use in the medical treatment and/or prophylaxis of virus infections |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH08506734A (ja) * | 1993-04-01 | 1996-07-23 | アイシス・ファーマシューティカルス・インコーポレーテッド | ｍＲＮＡキャップ活性に干渉しおよび翻訳を阻害するアンチセンスオリゴ類 |
| US20020166764A1 (en) * | 1997-08-12 | 2002-11-14 | University Of Southern California | Electrochemical sensor devices and methods for fast, reliable, and sensitive detection and quantitation of analytes |
| US20050020525A1 (en) * | 2002-02-20 | 2005-01-27 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
| BR0314236A (pt) * | 2002-09-13 | 2005-08-09 | Replicor Inc | Formulação de oligonucleotìdeo, composição farmacêutica, kit, composto antiviral, preparação de oligonucleotìdeo e métodos para seleção de um oligonucleotìdeo antiviral para uso como um agente antiviral, para profilaxia ou tratamento de uma infecção viral em um paciente, para tratamento profilático de câncer causado por oncovìrus, para identificação de um composto que altera a ligação de um oligonucleotìdeo a pelo menos um componente viral, para purificação da ligação de oligonucleotìdeos a pelo menos um componente viral e para enriquecimento de oligonucleotìdeos a partir de um agrupamento de oligonucleotìdeos |
| CN1694959A (zh) * | 2002-09-13 | 2005-11-09 | 雷普利瑟公司 | 非序列互补的抗病毒寡核苷酸 |
| WO2006042418A1 (en) | 2004-10-19 | 2006-04-27 | Replicor Inc. | Antiviral oligonucleotides |
| EP1942911A4 (en) | 2005-09-29 | 2009-08-19 | Replicor Inc | THERAPEUTIC MOLECULES AND USES THEREOF |
| WO2008017081A1 (en) * | 2006-08-04 | 2008-02-07 | Isis Pharmaceuticals, Inc. | Compositions and methods for the modulation of jnk proteins |
| WO2009065181A1 (en) * | 2007-11-21 | 2009-05-28 | Apollo Life Sciences Limited | Nanostructures suitable for delivery of agents |
| AU2009221064B2 (en) * | 2008-03-07 | 2014-12-11 | Roche Innovation Center Copenhagen A/S | Pharmaceutical compositions for treatment of microRNA related diseases |
| WO2010107838A1 (en) | 2009-03-16 | 2010-09-23 | Isis Pharmaceuticals, Inc. | Targeting apolipoprotein b for the reduction of apolipoprotein c-iii |
| EP2435571B1 (en) * | 2009-05-28 | 2016-12-14 | CuRNA, Inc. | Treatment of antiviral gene related diseases by inhibition of natural antisense transcript to an antiviral gene |
| CA2806616C (en) * | 2010-08-20 | 2015-08-11 | Replicor Inc. | Oligonucleotide chelate complexes |
-
2013
- 2013-05-16 AR ARP130101695A patent/AR091065A1/es not_active Application Discontinuation
- 2013-05-17 SI SI201331646T patent/SI2849760T1/sl unknown
- 2013-05-17 ES ES13791584T patent/ES2767333T3/es active Active
- 2013-05-17 WO PCT/CA2013/050378 patent/WO2013170385A1/en active Application Filing
- 2013-05-17 LT LTEP13791584.9T patent/LT2849760T/lt unknown
- 2013-05-17 EA EA201401276A patent/EA034799B1/ru unknown
- 2013-05-17 PT PT137915849T patent/PT2849760T/pt unknown
- 2013-05-17 NZ NZ701931A patent/NZ701931A/en unknown
- 2013-05-17 JP JP2015511876A patent/JP6294308B2/ja active Active
- 2013-05-17 HU HUE13791584A patent/HUE047456T2/hu unknown
- 2013-05-17 DK DK13791584.9T patent/DK2849760T3/da active
- 2013-05-17 AU AU2013262415A patent/AU2013262415B2/en active Active
- 2013-05-17 IN IN8982DEN2014 patent/IN2014DN08982A/en unknown
- 2013-05-17 MY MYPI2014003113A patent/MY168209A/en unknown
- 2013-05-17 SG SG11201407261XA patent/SG11201407261XA/en unknown
- 2013-05-17 RS RS20200065A patent/RS59914B1/sr unknown
- 2013-05-17 BR BR112014028568-3A patent/BR112014028568B1/pt active IP Right Grant
- 2013-05-17 US US13/896,427 patent/US9616083B2/en active Active
- 2013-05-17 CN CN201380025475.XA patent/CN104379152B/zh active Active
- 2013-05-17 EP EP13791584.9A patent/EP2849760B1/en active Active
- 2013-05-17 TW TW102117593A patent/TWI648288B/zh active
- 2013-05-17 KR KR1020147035251A patent/KR101975915B1/ko active IP Right Grant
- 2013-05-17 CA CA2873526A patent/CA2873526C/en active Active
- 2013-05-17 PL PL13791584T patent/PL2849760T3/pl unknown
- 2013-05-17 MX MX2014013885A patent/MX360626B/es active IP Right Grant
-
2014
- 2014-10-30 IL IL235402A patent/IL235402B/en unknown
- 2014-11-04 ZA ZA2014/08082A patent/ZA201408082B/en unknown
- 2014-11-06 PH PH12014502484A patent/PH12014502484B1/en unknown
- 2014-11-14 CR CR20140522A patent/CR20140522A/es unknown
- 2014-11-17 EC ECIEPI201427542A patent/ECSP14027542A/es unknown
- 2014-11-17 CU CU2014000132A patent/CU20140132A7/es unknown
- 2014-11-18 CL CL2014003135A patent/CL2014003135A1/es unknown
- 2014-11-18 DO DO2014000263A patent/DOP2014000263A/es unknown
- 2014-11-19 CO CO14254326A patent/CO7131388A2/es unknown
-
2015
- 2015-07-20 HK HK15106885.8A patent/HK1206259A1/xx unknown
-
2017
- 2017-11-02 JP JP2017212508A patent/JP2018058853A/ja active Pending
-
2020
- 2020-01-13 HR HRP20200045TT patent/HRP20200045T1/hr unknown
- 2020-01-21 CY CY20201100051T patent/CY1122856T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR091065A1 (es) | Una formulacion farmaceutica que comprende un quelato de oligonucleotidos antiviral para el tratamiento de una infeccion antiviral | |
| CL2021001195A1 (es) | Agentes de iarn para infección causada por el virus de la hepatitis b. (divisional de solicitud 201900278) | |
| NZ708392A (en) | Functionalized benzamide derivatives as antiviral agents against hbv infection | |
| BR112018075465A2 (pt) | agentes antivirais de hepatite b | |
| CL2021002747A1 (es) | Agentes antivirales para la hepatitis b (solicitud divisional no. 487-2020) | |
| BR112018067964A2 (pt) | agentes antivirais para hepatite b | |
| SI2709613T1 (en) | Procedures for the treatment of HCV | |
| WO2017027350A3 (en) | Rnai therapy for hepatitis b virus infection | |
| MX355267B (es) | Análogos de carba-nucleósido 2´-sustituidos para tratamiento antivírico. | |
| CO7051027A2 (es) | Agentes antivirales contra la hepatitis b | |
| CO6571891A2 (es) | Inhibidores del virus de la hepatitis c. | |
| BR112013020042A2 (pt) | inibidores de vírus da hepatite c | |
| BR112014019584A8 (pt) | Composto da fórmula (i), sua forma tautomérica, seu isômero, ou seu sal farmaceuticamente aceitável, composição farmacêutica, método de inibição da replicação de um vírus contendo rna, método de tratamento ou prevenção de infecção causada por um vírus contendo rna, e, método de tratamento de infecção por hepatite c | |
| CY1118399T1 (el) | Ενωσεις βενζοφουρανιου για την θεραπεια μολυνσεων ιου ηπατιτιδας c | |
| MA32841B1 (fr) | Composés de cycloundeca depsipeptides et leur utilisation comme médicament | |
| BR112014015582A8 (pt) | compostos antivirais | |
| EA201490963A1 (ru) | Новые производные гемина с антибактериальной и противовирусной активностью | |
| BR112014008464A2 (pt) | composto; composição farmacêutica; método para ligar dna de fita dupla com especificidade para sequência; método para reduzir ou inibir a proliferação de células de papiloma ou neoplásticas; método para tratar células infectadas por vírus; e método para tratar hpv em um indivíduo | |
| EA201892732A1 (ru) | Противовирусные средства для лечения гепатита в | |
| AR105611A1 (es) | TERAPIA ARNi PARA INFECCIÓN POR VIRUS DE HEPATITIS B | |
| EA201791848A1 (ru) | Композиция фосфорамидата нуклеотида | |
| AR085564A1 (es) | Uso de una region no codificante del genoma del virus de la fiebre aftosa para la eleboracion de un medicamento antiviral | |
| BR112013025934A2 (pt) | tratamento de infecção pelo vírus da hepatite c com alisporivir |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |